165 related articles for article (PubMed ID: 38585222)
1. Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients.
Wang S; Chen Y; Li W; Hao C; Zhang L; Zhao W; Shi Y; Tong Z
Breast Cancer (Dove Med Press); 2024; 16():163-179. PubMed ID: 38585222
[TBL] [Abstract][Full Text] [Related]
2. Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.
Lee CK; Davies L; Gebski VJ; Lord SJ; Di Leo A; Johnston S; Geyer C; Cameron D; Press MF; Ellis C; Loi S; Marschner I; Simes J; de Souza P
J Clin Oncol; 2016 Mar; 34(9):936-44. PubMed ID: 26811533
[TBL] [Abstract][Full Text] [Related]
3. Pilot Study on the Utility of Circulating HER2/Neu Levels in the Serum of Breast Cancer Patients.
Morgan S; Amemiya Y; Slodkowska E; Lu FI; Parra-Herran C; Nofech-Mozes S; Trudeau M; Olkhov-Mitsel E; Seth A; Hanna WM
Anticancer Res; 2019 Oct; 39(10):5345-5352. PubMed ID: 31570428
[TBL] [Abstract][Full Text] [Related]
4. Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment.
Zuo WJ; He M; Zheng H; Liu Y; Liu XY; Jiang YZ; Wang ZH; Lu RQ; Shao ZM
Gland Surg; 2021 Apr; 10(4):1300-1314. PubMed ID: 33968682
[TBL] [Abstract][Full Text] [Related]
5. Monitoring serum HER2 levels in breast cancer patients.
Tchou J; Lam L; Li YR; Edwards C; Ky B; Zhang H
Springerplus; 2015; 4():237. PubMed ID: 26069876
[TBL] [Abstract][Full Text] [Related]
6. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
Moreno-Aspitia A; Hillman DW; Dyar SH; Tenner KS; Gralow J; Kaufman PA; Davidson NE; Lafky JM; Reinholz MM; Lingle WL; Kutteh LA; Carney WP; Dueck AC; Perez EA
Cancer; 2013 Aug; 119(15):2675-82. PubMed ID: 23744760
[TBL] [Abstract][Full Text] [Related]
7. Clinical Relevance of Tissue and Serum Human Epidermal Growth Factor Receptor 2 Expression in Patients With Esophageal Squamous Cell Carcinoma.
Nagata H; Tsujimoto H; Horiguchi H; Sugasawa H; Kouzu K; Itazaki Y; Ishibashi Y; Tsuchiya S; Sugihara T; Ito N; Harada M; Nomura S; Kishi Y; Ueno H
J Surg Res; 2022 Jan; 269():189-200. PubMed ID: 34583287
[TBL] [Abstract][Full Text] [Related]
8. The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients.
Lee MH; Jung SY; Kang SH; Song EJ; Park IH; Kong SY; Kwon YM; Lee KS; Kang HS; Lee ES
PLoS One; 2016; 11(10):e0163370. PubMed ID: 27706242
[TBL] [Abstract][Full Text] [Related]
9. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
10. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
Witzel I; Loibl S; von Minckwitz G; Eidtmann H; Fehm T; Khandan F; Schmatloch S; Hauschild M; Bischoff J; Fasching PA; Mau C; Schem C; Rack B; Meinhold-Heerlein I; Liedtke C; Karn T; Huober J; Zu Eulenburg C; Issa-Nummer Y; Untch M; Müller V
Br J Cancer; 2012 Sep; 107(6):956-60. PubMed ID: 22892393
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: a systematic review and meta-analysis.
Zhang Z; Li C; Fan H; Xiang Q; Xu L; Liu Q; Zhou S; Xie Q; Chen S; Mu G; Cui Y
Breast Cancer Res Treat; 2018 Dec; 172(3):513-521. PubMed ID: 30159787
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of the Serum HER2 Extracellular Domain Level in Breast Cancer: A Systematic Review and Meta-Analysis.
Wu Y; Li L; Zhang D; Ma F
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230471
[TBL] [Abstract][Full Text] [Related]
14. A comparative clinical evaluation of the assay of serum extracellular domain of HER2 protein using a chemiluminescent immunoassay method in breast cancer patients with or without HER2 protein expression in immunohistochemistry.
Mokuyasu S; Suzuki Y; Seto T; Miyachi H; Tokuda Y
Rinsho Byori; 2012 Jul; 60(7):612-20. PubMed ID: 22973719
[TBL] [Abstract][Full Text] [Related]
15. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
Witzel I; Loibl S; von Minckwitz G; Mundhenke C; Huober J; Hanusch C; Henschen S; Hauschild M; Lantzsch T; Tesch H; Latos K; Just M; Hilfrich J; Barinoff J; Eulenburg CZ; Roller M; Untch M; Müller V
Breast Cancer Res Treat; 2010 Sep; 123(2):437-45. PubMed ID: 20623180
[TBL] [Abstract][Full Text] [Related]
16. Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status.
Soares M; Ribeiro R; Najmudin S; Gameiro A; Rodrigues R; Cardoso F; Ferreira F
Oncotarget; 2016 Apr; 7(14):17314-26. PubMed ID: 26909614
[TBL] [Abstract][Full Text] [Related]
17. The extracellular domain of Her2 in serum as a biomarker of breast cancer.
Perrier A; Gligorov J; Lefèvre G; Boissan M
Lab Invest; 2018 Jun; 98(6):696-707. PubMed ID: 29491426
[TBL] [Abstract][Full Text] [Related]
18. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
Li Y; Peng Z; Zhang X; Gong J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.
Wang J; Zhang B; Cheng X; Li Q; Lv H; Nie C; Chen B; Xu W; Zhao J; He Y; Tu S; Chen X
J Oncol; 2022; 2022():4233782. PubMed ID: 35368895
[TBL] [Abstract][Full Text] [Related]
20. [Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer].
Sang D; Song LH; Di LJ; Wang YL; Liu CG; Guo ZQ; Liu QY; Wang H; Li SY; Yuan P
Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):364-369. PubMed ID: 35448926
[No Abstract] [Full Text] [Related]
[Next] [New Search]
